Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 1, January-February, p. 97–102

Publication type: original article

Language: English

The Recovery of Immune System Parameters in Children Following Lymphoblastic Leukemia Therapy – Preliminary Report

Wojciech Pietras1,A,C,F, Radosław Chaber1,B,C,D, Halina Pela1,B,C,D, Katarzyna Trybucka1,B,C,D, Alicja Chybicka1,E

1 Department and Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Poland

Abstract

Background. Acute lymphoblastic leukemia (ALL) is the most common pediatric neoplasm. Long-term survival is achieved in approximately 80% of patients. One of the more common complications of ALL treatment is immunosuppression.
Objectives. The aim of the study is to assess the reconstruction rate of the most important immune system parameters in children after ALL treatment.
Material and Methods. The study included 47 children (22 boys, 25 girls) diagnosed and treated for ALL in Department of Pediatric Hematology and Oncology at Wroclaw Medical University. The study used peripheral blood collected at the time treatment was completed and in the first, second, third and sixth months following treatment, then at yearly intervals up to 10 years after treatment. In order to determine the immune status of the tested samples the following parameters were assessed: white blood cell count, absolute lymphocyte count, the proportions of individual subpopulations of lymphocytes – T (CD3 +), Th (CD4 +), Ts (CD8 +), B (CD19 +), NK (CD16 + 56 +), the concentration of immunoglobulins A, G and M, interleukin 10 activity, as well as the expression of ICAM-1 adhesion molecules.
Results. At the end of anti-neoplastic therapy a reduction in both the absolute number leukocytes and various subpopulations of lymphocytes was observed. The lower limits of normal range were achieved about two years after the end of treatment. The concentrations of immunoglobulin IgA, IgG and IgM at the end of treatment were within low normal limits. Normal concentrations of immunoglobulin levels and stability were observed about two years after the end of treatment. There was a slow, steady increase in the production of interleukin-10 and the expression of ICAM-1 adhesion molecules. These results confirm previous observations that after ALL treatment children are in an immunocompromised state for up to 12 months, in terms of both humoral and cellular immunity.
Conclusion. Knowing the average growth trends for the main immune system parameters after ALL treatment can be important in clinical practice for children in whom immune reconstruction proceeds slowly. Predicting the expected time required to restore immune function could be of help, for example in combating infections and planning vaccinations.

Key words

acute lymphoblastic leukemia, immune system, reconstruction.

References (21)

  1. Eds. Deborah Tomlinson, Nancy E: Kline Pediatric Oncology Nursing: Advanced Clinical Handbook. 2nd ed. Part 1.2 Acute Lymphoblastic Leukemia ed. S. Zupanec, D. Tomlinson. p 3, Springer-Verlag Berlin Heidelberg 2005, 2010.
  2. Luczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, Zak J: Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections. Wiad Lek 2004, 57, 337–342.
  3. Martín Ibáñez I, Arce Casas A, Cruz Martínez O, Estella Aguado J, Martín Mateos MA: Humoral immunity in pediatric patients with acute lymphoblastic leukaemia. Allergol Immunopathol (Madr) 2003, 31, 303–310.
  4. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG: Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia – a prospective study of 20 paediatric patients. Br J Haematol 2009, 147, 360–370. Epub 2009 Aug 19.
  5. Ek T, Mellander L, Andersson B, Abrahamsson J: Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005, 44, 461–468.
  6. Alanko S, Salmi TT, Pelliniemi TT: Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994, 11, 281–292.
  7. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b. J Pediatr Hematol Oncol 2004, 26, 727–734.
  8. Lehrnbecher T, Schubert R, Behl M, Koenig M, Rose MA, Koehl U, Meisel R, Laws HJ: Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. Br J Haematol. 2009, 147, 700–705. Epub 2009 Sep 18.
  9. Calaminus G, Hense B, Laws HJ, Groeger M, MacKenzie CR, Göbel U: Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92. Klin Padiatr 2007, 219, 355–360.
  10. Mustafa MM, Buchanan GR, Winick NJ, McCracken GH, Tkaczewski I, Lipscomb M, Ansari Q, Agopian MS: Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 1998, 20, 451–457.
  11. Kovacs GT, Barany O, Schlick B, Csoka M, Gado J, Ponyi A, Müller J, Nemeth J, Hauser P, Erdelyi DJ: Late immune recovery in children treated for malignant diseases. Pathol Oncol Res. 2008, 14, 391–397. Epub 2008 Jun 25.
  12. Alanko S, Salmi TT, Pelliniemi TT: Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol 1995, 24, 373–378.
  13. De Angulo G, Yuen C, Palla S, Anderson PM, Zweidler-McKay PA: Absolute Lymphocyte Count Is a Novel Prognostic Indicator in ALL and AML. Implications for Risk Stratification and Future Studies. Cancer 2008, 112, 407–415.
  14. Nilsson A, De Milito A, Engström P, Nordin M, Narita M, Grillner L, Chiodi F, Björk O: Current Chemotherapy Protocols for Childhood Acute Lymphoblastic Leukemia Induce Loss of Humoral Immunity to Viral Vaccination Antigens. Pediatrics 2002, 109. URL: http://www.pediatrics.org/cgi/content/full/109/6/e91.
  15. Mackall C, Fleisher T, Brown M: Age, thymopoesis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332, 143–149.
  16. Azuma E, Nagai M, Qi J: CD4+ T-lymphocytopenia in long term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol 1998, 30, 40–45.
  17. de Vaan GAM, van Munster PJJ, Bakkeren JAJM: Recovery of immune function after cessation of maintenance therapy in acute lymphoblastic leukemia (ALL) of childhood. Eur J Pediatr 1982, 139, 113–117.
  18. Mazur B, Olejnik I, Sońta-Jakimczyk D, Bubała H: Stężenie IgE i limfocyty CD23+ u dzieci po zakończeniu leczenia ostrej białaczki limfoblastycznej. Alergia Astma Immunol 2000, 5, 197–200.
  19. Lissoni P, Rovellli F, Pittalis S, Casati M, Perego MS, Grassi MG, Brivo F, Fumagali L: Interleukin-12 in early or advanced cancer patients. Eur J Cancer 1997, 33, 1703–1705.
  20. Tacyildiz N, Yavuz G, Gozdasoglu S, Unal E, Ertem U, Duru F, Ikinciogullari A, Babacan E, Ensari A, OkcuogluCavdar A: Serum levels and differential expression of intercellular adhesiom molecule-1 in childhood leukemia and malignant lymphoma: prognostic importance and relationship with survival. Pediatr Hematol Oncol 1999, 16, 149–158.
  21. Kabelmann-Betzing C, Korner G, Badiali L, Buchwald D, Moricke A, Korte A, Kochling A, Wu S, Kappelmeier D, Oettel K, Henze G, Seeger K: Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all. Cytokine 2001, 7, 13, 39–50.
© Wroclaw Medical University